GT Biopharma Inc GTBP 深 滬
等待開盤 08-10 09:30:00 美东时间
0.3201
+0.019
+6.35%
華盛通- 最 高0.3275
- 今 開0.301
- 成交量 57.09万股
- 最 低 0.301
- 昨 收 0.301
- 總市值 1419.28万
- 52周最高 1.5257
- 市盈率 靜 --
- 換手率 1.29%
- 52周最低 0.261
- 委 比 88.23%
- 總股本 4433.86万
- 歷史最高 591.99
- 量 比 1.46
- 振 幅 8.80%
- 歷史最低 0.261
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GT Biopharma Lowers Stockholder Quorum to One-Third
GT Biopharma ( ($GTBP) ) has provided an announcement. On June 8, 2026, GT Biop...
06-13 07:02
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.
06-01 19:31
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
GT Biopharma is leveraging AI-based tools to accelerate the development of tumor-targeting engagers and multi-domain proteins, reducing costs and reliance on trial-and-error experimentation. These technologies enhance binding, stability, and functional activity, shortening timelines and increasing the likelihood of translational success. The company expects multiple new development candidates to enter pre-IND development in 2027, with potential a...
06-01 12:00
Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/109657/000149315226024913/form8-k.htm
05-22 20:11
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically pe...
05-19 02:22
GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 66.67 percent increase over losses of $(0.33) per share from the
05-15 20:19
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma announced its Q1 2026 financial results, highlighting $9 million in cash and ongoing Phase 1 trials for GTB-3650 and GTB-5550. GTB-3650 targets CD33-positive leukemias, with enrollment progressing through dose escalation cohorts. GTB-5550, the first subcutaneously administered TriKE, focuses on B7-H3-positive solid tumors, with enrollment ongoing across multiple tumor types. The company expects updates on both programs in H2 2026. GT...
05-15 12:00
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.
05-14 20:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
